Dosimetry of ¹³¹I in remnant ablation and metastasis of differentiated thyroid cancer treated with high radioactivities and rhTSH

References

• Nylén, C.; Mechera, R.; Maréchal-Ross, I.; Tsang, V.; Chou, A.; Gill, A.J.; Clifton-Bligh, R.J.; Robinson, B.G.; Sywak, M.S.; Sidhu, S.B.; Glover, A.R. Molecular Markers Guiding Thyroid Cancer Management. Cancers. (Basel) 2020, 12 (8), 2164. DOI:10.3390/cancers12082164.
   PubMed Web of Science ®Google Scholar
• Cabanillas, M.E.; McFadden, D.G.; Durante, C. Thyroid Cancer. Lancet 2016, 388 (10061), 2783–2795. DOI:10.1016/S0140-6736(16)30172-6.
   PubMed Web of Science ®Google Scholar
• Lim, H.; Devesa, S.S.; Sosa, J.A.; Check, D.; Kitahara, C.M. Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013. JAMA 2017, 317 (13), 1338–1348. DOI:10.1001/jama.2017.2719.
   PubMed Web of Science ®Google Scholar
• La Vecchia, C.; Malvezzi, M.; Bosetti, C.; Garavello, W.; Bertuccio, P.; Levi, F.; Negri, E. Thyroid Cancer Mortality and Incidence: A Global Overview. Int. J. Cancer 2015, 136 (9), 2187–2195. DOI:10.1002/ijc.29251.
   PubMed Web of Science ®Google Scholar
• Nikitski, A.V.; Rominski, S.L.; Wankhede, M.; Kelly, L.M.; Panebianco, F.; Barila, G.; Altschuler, D.L.; Nikiforov, Y.E. Mouse Model of Poorly Differentiated Thyroid Carcinoma Driven by STRN-ALK Fusion. Am. J. Pathol. 2018, 188 (11), 2653–2661. DOI:10.1016/j.ajpath.2018.07.012.
   PubMed Web of Science ®Google Scholar
• Park, H.S.; Roman, S.A.; Sosa, J.A. Treatment Patterns of Aging Americans with Differentiated Thyroid Cancer. Cancer 2010, 116 (1), 20–30. DOI:10.1002/cncr.24717.
   PubMed Web of Science ®Google Scholar
• Verburg, F.A.; Luster, M.; Giovanella, L. Adjuvant Post-Operative I-131 Therapy in Differentiated Thyroid Carcinoma: Are the 2015 ATA Guidelines an Exact Science or a Dark art? Eur. J. Nucl. Med. Mol. Imaging 2017, 44 (2), 183–184. DOI:10.1007/s00259-016-3526-y.
   PubMed Web of Science ®Google Scholar
• Eckerman, K.; Endo, A. User Guide to the ICRP CD and the DECDATA Software. Ann. ICRP 2008, 38 (3), e1–e25. DOI:10.1016/j.icrp.2008.10.001.
   PubMedGoogle Scholar
• Hall, E. J.; Giaccia, A. J. Radiobiology for the Radiologist, 8th ed. Lippincott Williams & Wilkins (LWW): Philadelphia, 2018.
   Google Scholar
• Parisi, M.T.; Khalatbari, H.; Parikh, S.R.; Alazraki, A. Initial Treatment of Pediatric Differentiated Thyroid Cancer: A Review of the Current Risk-Adaptive Approach. Pediatr. Radiol. 2019, 49 (11), 1391–1403. DOI:10.1007/s00247-019-04457-7.
   PubMed Web of Science ®Google Scholar
• Bacher, R.; Hohberg, M.; Dietlein, M.; Wild, M.; Kobe, C.; Drzezga, A.; Schmidt, M. Thyroid Uptake and Effective Half-Life of Radioiodine in Thyroid Cancer Patients at Radioiodine Therapy and Follow-Up Whole-Body Scintigraphy Either in Hypothyroidism or Under rhTSH. J. Nucl. Med. 2019, 60 (5), 631–637. DOI:10.2967/jnumed.118.217638.
   PubMed Web of Science ®Google Scholar
• Stanciu, A.E.; Hurduc, A.E.; Stanciu, M.M. Effects of Thyroid Hormone Withdrawal on Natriuretic Peptides During Radioactive Iodine Therapy in Female Patients with Differentiated Thyroid Cancer. Scand. J. Clin. Lab. Invest. 2016, 76 (8), 626–631. DOI:10.1080/00365513.2016.1230883.
   PubMed Web of Science ®Google Scholar
• Piccardo, A.; Puntoni, M.; Ferrarazzo, G.; Foppiani, L.; Bottoni, G.; Altrinetti, V.; Treglia, G.; Naseri, M.; Dib, B.; Cabria, M.; Trimboli, P.; Massollo, M.; Giovanella, L. Could Short Thyroid Hormone Withdrawal be an Effective Strategy for Radioiodine Remnant Ablation in Differentiated Thyroid Cancer Patients? Eur. J. Nucl. Med. Mol. Imaging 2018, 45 (7), 1218–1223. DOI:10.1007/s00259-018-3955-x.
   PubMed Web of Science ®Google Scholar
• Oberstadt, A.E.; Nelson, N.C.; Claude, A.K.; Refsal, K.R.; Scott-Moncrieff, J.C.; Petroff, B.K.; Langlois, D.K. Radioactive Iodine Uptake in Hyperthyroid Cats After Administration of Recombinant Human Thyroid Stimulating Hormone. J. Vet. Intern. Med. 2018, 32 (6), 1891–1896. DOI:10.1111/jvim.15295.
   PubMed Web of Science ®Google Scholar
• Lassmann, M.; Luster, M.; Thomas, S.R.; Pacini, F.; Ceccarelli, C.; Ladenson, P.W.; Wahl, R.L.; Schlumberger, M.; Marcel Ricard, A.D.; Kloos, R.T.; Sherman, S.I.; Haugen, B.R.; Carriere, V.; Corone, C. Iodine Biokinetics and Dosimetry in Radioiodine Therapy of Thyroid Cancer: Procedures and Results of a Prospective International Controlled Study of Ablation After rhTSH or Hormone Withdrawal. J. Nucl. Med. 2006, 47 (4), 648–654.
   PubMed Web of Science ®Google Scholar
• Klubo-Gwiezdzinska, J.; Burman, K.D.; Van Nostrand, D.; Mete, M.; Jonklaas, J.; Wartofsky, L. Potential use of Recombinant Human Thyrotropin in the Treatment of Distant Metastases in Patients with Differentiated Thyroid Cancer. Endocr. Pract. 2013, 19 (1), 139–148. DOI:10.4158/EP12244.RA.
   PubMed Web of Science ®Google Scholar
• Ravichandran, R.; Binukumar, J.; Saadi, A.A. Estimation of Effective Half Life of Clearance of Radioactive Iodine (131I) in Patients Treated for Hyperthyroidism and Carcinoma Thyroid. Indian. J. Nucl. Med. 2010, 25 (2), 49–52. DOI:10.4103/0972-3919.72686.
   PubMedGoogle Scholar
• Siegel, J.A.; Thomas, S.R.; Stubbs, J.B.; Stabin, M.G.; Hays, M.T.; Koral, K.F.; Robertson, J.S.; Howell, R.W.; Wessels, B.W.; Fisher, D.R.; Weber, D.A.; Bertrand Brill, A. MIRD Pamphlet no. 16: Techniques for Quantitative Radiopharmaceutical Biodistribution Data Acquisition and Analysis for use in Human Radiation Dose Estimates. J. Nucl. Med. 1999, 40 (2), 37S–61S.
   PubMed Web of Science ®Google Scholar
• Buijs, W.C.A.M.; Siegel, J.A.; Boerman, O.C.; Corstens, F.H.M. Absolute Organ Activity Estimated by Five Different Methods of Background Correction. J. Nucl. Med. 1998, 39 (12), 2167–2172.
   PubMed Web of Science ®Google Scholar
• Macey, D.J.; Grant, E.J.; Bayouth, J.E.; Giap, H.B.; Danna, S.J.; Sirisriro, R.; Podoloff, D.A. Improved Conjugate View Quantitation of I-131 by Subtraction of Scatter and Septal Penetration Events with a Triple Energy Window Method. Med. Phys. 1995, 22 (10), 1637–1643. DOI:10.1118/1.597423.
   PubMed Web of Science ®Google Scholar
• Stabin, M.G.; Sparks, R.B.; Crowe, E. OLINDA/EXM: The Second-Generation Personal Computer Software for Internal Dose Assessment in Nuclear Medicine. J. Nucl. Med. 2005, 46, 1023–1028. DOI: 46/6/1023[pii].
   PubMed Web of Science ®Google Scholar
• Riesco-Eizaguirre, G.; Santisteban, P. Transportador de Yodo (NIS) y su Aplicación Diagnóstica y Terapéutica en Diferentes Enfermedades. Endocrinología y Nutrición 2008, 55 (3), 107–110. DOI:10.1016/S1575-0922(08)70645-4.
   PubMedGoogle Scholar
• Haugen, B.R.; Alexander, E.K.; Bible, K.C.; Doherty, G.M.; Mandel, S.J.; Nikiforov, Y.E.; Pacini, F.; Randolph, G.W.; Sawka, A.M.; Schlumberger, M.; Schuff, K.G.; Sherman, S.I.; Sosa, J.A.; Steward, D.L.; Tuttle, R.M.; Wartofsky, L. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016, 26 (1), 1–133. DOI:10.1089/thy.2015.0020.
   PubMed Web of Science ®Google Scholar
• Over, R.; Nsouli-Maktabi, H.; Burman, K.D.; Jonklaas, J. Age Modifies the Response to Recombinant Human Thyrotropin. Thyroid 2010, 20 (12), 1377–1384. DOI:10.1089/thy.2010.0177.
   PubMed Web of Science ®Google Scholar
• Holthausen, F.F.; von Müller, F.; Happel, C.; Kranert, W.T.; Grünwald, F. Age and Body Composition Influence TSH Concentrations After Administration of rhTSH. NuklearMedizin 2015, 54 (1), 20–25. DOI:10.3413/Nukmed-0673-14-06.
   PubMedGoogle Scholar
• Torres, M.S.T.; Ramirez, L.; Simkin, P.H.; Braverman, L.E.; Emerson, C.H. Effect of Various Doses of Recombinant Human Thyrotropin on the Thyroid Radioactive Iodine Uptake and Serum Levels of Thyroid Hormones and Thyroglobulin in Normal Subjects. J. Clin. Endocrinol. Metab. 2001, 86 (4), 1660–1664. DOI:10.1210/jcem.86.4.7405.
   PubMed Web of Science ®Google Scholar
• Ruiz, M.A.; Ferrer García, N.; Córdoba, D.; Iracheta, L.A.; Sastre, J.M.; Arranz, L. Dosimetría de Pacientes con Cáncer Diferenciado de Tiroides en Tratamiento de Terapia Metabólica con 131 I a Partir de Medidas de Tasa de Dosis Externa. Rev. Física Médica 2010, 11 (1), 35–42.
   Google Scholar
• Dauer, L.T.; St. Germain, J.; Williamson, M.J.; Zanzonico, P.; Modak, S.; Cheung, N.-K.; Divgi, C. Whole-body Clearance Kinetics and External Dosimetry of 131I-3F8 Monoclonal Antibody for Radioimmunotherapy of Neuroblastoma. Health Phys. 2007, 92 (1), 33–39. DOI:10.1097/01.HP.0000231583.32904.6c.
   PubMed Web of Science ®Google Scholar
• Alan Selcuk, N.; Toklu, T.; Beykan, S.; Karaaslan, S.I. Evaluation of the Dosimetry Approaches in Ablation Treatment of Thyroid Cancer. J. Appl. Clin. Med. Phys. 2018, 19 (4), 134–140. DOI:10.1002/acm2.12350.
   PubMed Web of Science ®Google Scholar
• Maxon, H.R.; Thomas, S.R.; Hertzberg, V.S.; Kereiakes, J.G.; Chen, I.-W.; Sperling, M.I.; Saenger, E.L. Relation Between Effective Radiation Dose and Outcome of Radioiodine Therapy for Thyroid Cancer. N. Engl. J. Med. 1983, 309 (16), 937–941. DOI:10.1056/NEJM198310203091601.
   PubMed Web of Science ®Google Scholar